Heterophilic antibody interference in a non-endogenous molecule assay: An apparent elevation in the tacrolimus concentration

被引:24
作者
Altinier, Sara [1 ]
Varagnolo, Mariacristina [1 ]
Zaninotto, Martina [1 ]
Boccagni, Patrizia [2 ]
Plebani, Mario [1 ]
机构
[1] Univ Hosp Padova, Dept Lab Med, I-35128 Padua, Italy
[2] Univ Padua, Surg Endoscopy Unit, Dept Surg & Gastroenterol Sci, I-35100 Padua, Italy
关键词
Tacrolimus; Heterophilic antibody; Interference assay; CLINICAL-CHEMISTRY ANALYZER; PHARMACOKINETICS; LABORATORIES; FK506; BLOOD;
D O I
10.1016/j.cca.2008.12.021
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: In drug monitoring assays the most common interferences are due to hematocrit, other drugs or their metabolites, while the interference by heterophilic antibodies has been reported only when measuring endogenous molecules. In the present paper a heterophilic antibody interference in the tacrolimus measurement is described. Methods: Samples from a patient treated with tacrolimus were analyzed on RxL Dimension analyzer. Ranging drug concentrations from 49 to 12.5 mu g/L, even after the interruption of the treatment, confirmation analysis were performed using heterophilic blocking tubes before tacrolimus measurement on the same analyzer, then testing the samples on V-Twin System, finally incubating the samples with chlorophenol red beta-d-galactopyranoside, beta-galactosidase, polyclonal mouse IgG, protein A and Protein G resin. Results: The elevated tacrolimus concentrations were due to the presence of an interference attributable to heterophilic antibodies, as confirmed by treating the samples with heterophilic blocking tubes and protein G resin. Conclusions: a) The interference caused by heterophilic antibodies can be found not only in immunoassays measuring endogenous molecules, but also in those for exogenous molecules: b) the pre-treatment sample procedure, which represent the main difference between the methods affected and unaffected by the interference, is a fundamental step in removing the antibodies responsible of the interference. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:193 / 195
页数:3
相关论文
共 9 条
[1]   Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods [J].
Akbas, SH ;
Ozdem, S ;
Caglar, S ;
Tuncer, M ;
Gurkan, A ;
Yucetin, L ;
Senol, Y ;
Demirbas, A ;
Gultekin, M ;
Ersoy, FF ;
Akaydin, M .
CLINICAL BIOCHEMISTRY, 2005, 38 (06) :552-557
[2]   The V-twin system (Dade Behring Laboratories): A useful tool for immunosuppressive drug monitoring [J].
Elaerts, S ;
Olejnik, Y ;
Bonardet, A ;
Garrigue, V ;
Mourad, G ;
Cristol, JP ;
Dupuy, AM .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (01) :167-171
[3]   Screening for interference in immunoassays [J].
Emerson, JF ;
Ngo, G ;
Emerson, SS .
CLINICAL CHEMISTRY, 2003, 49 (07) :1163-1169
[4]   Performance of a no-pretreatment tacrolimus assay on the Dade Behring Dimension RxL clinical chemistry analyzer [J].
Griffey, Megan A. ;
Hock, Karl G. ;
Kilgore, Daniel C. ;
Wei, Tie Q. ;
Duh, Show-Hong ;
Christenson, Robert ;
Scott, Mitchell G. .
CLINICA CHIMICA ACTA, 2007, 384 (1-2) :48-51
[5]   Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics [J].
Iwasaki, Kazuhide .
DRUG METABOLISM AND PHARMACOKINETICS, 2007, 22 (05) :328-335
[6]  
Marks V, 2002, CLIN CHEM, V48, P2008
[7]   DISTRIBUTION AND PROTEIN-BINDING OF FK506, A POTENT IMMUNOSUPPRESSIVE MACROLIDE LACTONE, IN HUMAN BLOOD AND ITS UPTAKE BY ERYTHROCYTES [J].
NAGASE, K ;
IWASAKI, K ;
NOZAKI, K ;
NODA, K .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1994, 46 (02) :113-117
[8]   Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation [J].
Staatz, CE ;
Tett, SE .
CLINICAL PHARMACOKINETICS, 2004, 43 (10) :623-653
[9]  
Terrell AR, 2002, CLIN CHEM, V48, P1059